London, [00.00am, 11th May 2026]: Sava Technologies Ltd., the London-based health technology company developing a minimally invasive molecular sensing platform, today announces that John Bernard has joined the company as Chief Commercial Officer. The move marks a decisive step in Sava’s transition from clinical and technical progress to commercial execution.
Bernard brings more than two decades of international commercial leadership across healthcare and technology, including seven years at Dexcom, where he was a core member of the EMEA executive leadership team. During his tenure, he led growth across more than 40 markets, co-created Dexcom ONE and was responsible for the global launch of G7. Earlier in his career, he also held senior roles at Siemens, LG, Mozilla and Sony.
He joins Sava at a time of accelerating demand for CGM (Continuous Glucose Monitoring) technologies and growing commercial opportunity across international diabetes markets. The CGM market is forecasted to generate approximately $14.3 billion in annual sales globally in 2026, with around 12 million users worldwide. This represents only a fraction of the estimated 589 million adults aged 20-79 years living with diabetes, a figure projected to rise to 853 million by 2050.
Despite this accelerating demand, the global CGM market remains a duopoly dominated by two manufacturers, leaving distributors, clinicians and patients with limited access to differentiated technologies. Sava is building its market entry strategy around this opportunity, with advanced commercial discussions already underway with leading distributors across major diabetes markets in Europe and internationally, as demand grows for new entrants capable of expanding choice and innovation in the category. Bernard brings the category experience and international execution track record required to convert that momentum into long-term commercial scale.
Renato Circi, Co-Founder and Co-CEO at Sava, said:
“John’s appointment marks a shift in philosophy at Sava as we move our focus from the design phase to bringing our platform to people worldwide. Sava hasn’t set out to launch “another CGM.” We’ve spent years engineering something fundamentally different: a more elevated user experience delivering deeper insights that go beyond glucose alone. Designed around what people want, not just what they clinically need. John helped bring CGM to market when it was still a completely new way of sensing. Now, he’ll help bring to life the next generation of monitoring. Something new. Something better.”
John Bernard, Chief Commercial Officer at Sava, said:
Across Europe and beyond, there is strong demand for truly differentiated platforms built for long-term scale. Our focus now is disciplined execution, converting this early traction into commercial partnerships and bringing Sava’s next-generation microsensing technology to people living with type 1 and type 2 diabetes.
About Sava
Sava is a venture-backed consumer and medical device company developing an innovative wearable biosensor platform that can detect molecules just under the skin. Headquartered in London, the company has developed a novel microsensor technology that monitors biomarkers in the body in a painless, real-time and affordable way, starting with, but not limited to, glucose.
Techedge AI is a niche publication dedicated to keeping its audience at the forefront of the rapidly evolving AI technology landscape. With a sharp focus on emerging trends, groundbreaking innovations, and expert insights, we cover everything from C-suite interviews and industry news to in-depth articles, podcasts, press releases, and guest posts. Join us as we explore the AI technologies shaping tomorrow’s world.
